Logos Capital, a San Francisco-based venture fund established in 2019, specializes in Series B, C, and D investments in Biotech, Life Science, Healthcare, and Medical Device sectors. Led by Partner Arsani William, the fund has invested in companies like Parse Biosciences, Gennao Bio, and Odyssey Therapeutics. With 86 investments and 45 exits, Logos Capital focuses on fundamental biotechnology investments. For more details, visit their website at logoscapital.com.